One Nucleus announces life science award shortlist

One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies with exciting developments. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced.

Companies and research organisations were nominated for their most important updates from the last year. These were assessed based on their impact on the organisation, whether they demonstrated an exciting development in the life sciences sector or whether they have the potential to significantly benefit patients. This year’s nominations were particularly competitive, with 30 news stories submitted. The finalists are listed below:

Abcam IPO – Abcam Announces Pricing of Offering on NASDAQ

Catalent – Catalent Completes Acquisition of MaSTherCell

Cellen – Online Clinic Launched for Patients Living with Persistent Pain

Oxeia – Announces Initiation of Phase 2 Trial for OXE103

Salvia BioElectronics – Salvia BioElectronics Receives FDA Breakthrough Device Designation for Innovative Neurostimulation Solution

Storm Therapeutics – Storm Therapeutics Selects First-in-Class Clinical Candidate Targeting METTL3

A video of each finalist’s pitch will be available to registered delegates via the conference app in the run up to Genesis. Delegates can then vote via a poll on the app and the winner will be announced at the culmination of the prestigious annual Genesis conference, held virtually this year on 10th December.

Genesis 2020, which will take place on 10 December, will assemble senior executives and decision-makers from across the life science, healthcare and technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders.

Image credit: Georgio Trovato



Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free